Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study

被引：0

作者：

Strand, Vibeke ^{[1
]}

Reaney, Matthew ^{[2
]}

Mangan, Erin ^{[3
]}

van Hoogstraten, Hubert ^{[4
]}

Boklage, Susan ^{[3
]}

Hu, Chih-Chi ^{[5
]}

机构：

[1] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA

[2] Sanofi, Guildford, Surrey, England

[3] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[4] Sanofi Genzyme, Bridgewater, NJ USA

[5] Sanofi, Bridgewater, NJ USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2549

引用

页数：2

共 50 条

[1] PATIENT REPORTED BENEFITS OF SARILUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN ADULT PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Strand, V.
Gossec, L.
Proudfoot, C.
Chen, C.
Reaney, M.
Guillonneau, S.
Kimura, T.
van Adelsberg, J.
Lin, Y.
Mangan, E.
van Hoogstraten, H.
Burmester, G. R.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 94 - 94
[2] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RHEUMATOID ARTHRITIS PATIENTS
Genovese, Mark C.
Fay, Jon
Parrino, Janie
Beyer, Doris
Iglesias-Rodriguez, Melitza
Graham, Neil
Boddy, Alex
Martincova, Renata
Burmester, Gerd R.
RHEUMATOLOGY, 2017, 56 : 139 - 139
[3] Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-Label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
Burmester, Gerd R.
Fiore, Stefano
Hu, Chih-Chi
Fay, Jonathan
Lee, Eun Bong
Genovese, Mark C.
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[4] Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
Burmester, Gerd
Fiore, Stefano
Hu, Chih-Chi
Fay, Jonathan
Lee, Eun-Bong
Genovese, Mark
JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 1035 - 1035
[5] EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSION OF A PHASE 3 MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)
Burmester, G. R.
Fiore, S.
Hu, C-C
van Hoogstraten, H.
Lee, Bong E.
Genovese, M. C.
INTERNAL MEDICINE JOURNAL, 2018, 48 : 21 - 21
[6] EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSIONOF A PHASE III MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Burrnester, Gerd R.
Fiore, Stefano
Hu, Chih-Chi
Fay, Jon
Lee, Eun Bong
Genovese, Mark C.
RHEUMATOLOGY, 2018, 57
[7] Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Strand, Vibeke
Gossec, Laure
Proudfoot, Clare W. J.
Chen, Chieh-I
Reaney, Matthew
Guillonneau, Sophie
Kimura, Toshio
van Adelsberg, Janet
Lin, Yong
Mangan, Erin K.
van Hoogstraten, Hubert
Burmester, Gerd R.
ARTHRITIS RESEARCH & THERAPY, 2018, 20
[8] Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Vibeke Strand
Laure Gossec
Clare W. J. Proudfoot
Chieh-I Chen
Matthew Reaney
Sophie Guillonneau
Toshio Kimura
Janet van Adelsberg
Yong Lin
Erin K. Mangan
Hubert van Hoogstraten
Gerd R. Burmester
Arthritis Research & Therapy, 20
[9] Patient-Reported Outcomes of Long-Term Upadacitinib Use in Patients with Rheumatoid Arthritis: Interim Analysis Results of a Phase 2, Open-Label Extension Study
Strand, Vibeke
Tundia, Namita
Friedman, Alan
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[10] GLUCOCORTICOID DOSE IS PROGRESSIVELY REDUCED IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING SARILUMAB: RESULTS FROM THE OPEN-LABEL EXTEND STUDY
Fleischmann, Roy
Selmi, Carlo
Gonzalez-Gay, Miguel Angel
van Hoogstraten, Hubert
Hagino, Owen
Rajput, Tejasweeni
St John, Gregory
Buttgereit, Frank
Genovese, Mark C.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 80 - 80

← 1 2 3 4 5 →